With the increase in advertisement medication for obesity management, many individuals purchase online GLP-1receptor agonists . A recent article in Jama network highlighted specific issues that should concern DCES. Chetty et al. found that most online GLP‑1 RA vendors issued prescriptions with minimal clinician involvement, relying heavily on patient‑reported questionnaires that may omit critical clinical and psychosocial details. DCES should counsel their patients that rapid online prescribing may bypass essential safety checks, including verification of comorbidities, medication interactions, and eating‑disorder risk.
Patients should also be advised that some sites prescribe or dispense compounded GLP‑1 products, which may carry additional medical and financial risks due to variable quality and limited regulatory oversight. In my clinic that cares for individuals with obesity and diabetes, I emphasize the importance of clinician‑guided assessment to ensure appropriate therapy selection, monitoring, and long‑term weight and glycemic management.
https://jamanetwork.com/journals/jama/fullarticle/2851149
https://www.renalandurologynews.com/news/no-clinician-interaction-needed-for-many-online-glp-1-receptor-agonist-prescribers/
https://medicalxpress.com/news/2026-07-glp-secret-shopper-gaps-online.html